Posted by Michael Wonder on 20 Sep 2021
Aveo Oncology announces ficlatuzumab granted fast track designation by the U.S. FDA for the treatment of relapsed or recurrent head and neck squamous cell carcinoma
20 September 2021 - Aveo Oncology today announced that the U.S. FDA has granted fast frack designation to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma.
Ficlatuzumab is Aveo’s investigational potent humanised immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor.
